



Cite this: *Org. Biomol. Chem.*, 2014, **12**, 8598

Received 14th August 2014,  
Accepted 17th September 2014

DOI: 10.1039/c4ob01738b

www.rsc.org/obc

## Organocatalysts of oxidative protein folding inspired by protein disulfide isomerase†


John C. Lukesh III,<sup>‡a</sup> Kristen A. Andersen,<sup>‡b</sup> Kelly K. Wallin<sup>c</sup> and Ronald T. Raines<sup>\*a,c</sup>

**Organocatalysts derived from diethylenetriamine effect the rapid isomerization of non-native protein disulfide bonds to native ones. These catalysts contain a pendant hydrophobic moiety to encourage interaction with the non-native state, and two thiol groups with low  $pK_a$  values that form a disulfide bond with a high  $E^\circ$  value.**

The formation of native disulfide bonds is at the core of oxidative protein folding.<sup>1–4</sup> In oxidizing environments, reduced proteins with multiple cysteine residues tend to oxidize rapidly and nonspecifically. To attain a proper three-dimensional fold, any non-native disulfide bonds must isomerize to the linkages found in the native protein.<sup>5</sup> In eukaryotic cells, this process is mediated by the enzyme protein disulfide isomerase (PDI; EC 5.3.4.1).<sup>4,6–14</sup>

Catalysis of disulfide-bond isomerization by PDI involves thiol–disulfide interchange chemistry. A putative mechanism commences with the nucleophilic attack by a thiolate on a non-native disulfide bond, generating a mixed-disulfide and a new substrate thiolate (Fig. 1).<sup>15</sup> This thiolate can then attack another non-native disulfide bond, inducing further rearrangements to achieve the stable native state. The ability of PDI to catalyze disulfide-bond isomerization (rather than dithiol oxidation) makes the enzyme essential to the viability of the yeast *Saccharomyces cerevisiae*.<sup>7,16</sup>

PDI is abundant in the endoplasmic reticulum (ER) of eukaryotic cells. The enzyme contains four domains: a, a', b, and b'.<sup>12</sup> The a and a' domains each contain one active-site CGHC motif—a pattern analogous to that in many other oxidoreductases, whereas the b and b' domains appear to mediate



**Fig. 1** Putative mechanism for catalysis of protein-disulfide isomerization by protein disulfide isomerase (PDI) and small-molecule dithiol catalysts.

substrate binding.<sup>12,17,18</sup> The physicochemical properties of its active-site make PDI an ideal catalyst for the reshuffling of disulfide bonds in misfolded proteins. The deprotonated thiolate of its N-terminal active-site cysteine residue (CGHC) initiates catalysis (Fig. 1).<sup>19</sup> The amount of enzymic thiolate present is dependent on two factors.<sup>20,21</sup> One is the  $pK_a$  of the active-site cysteine residue; the other is the reduction potential ( $E^\circ$ ) of the disulfide bond formed between the two active-site cysteine residues. In PDI, the cysteine  $pK_a$  is 6.7, and the disulfide  $E^\circ$  is  $-0.18$  V.<sup>22,23</sup> Given the properties of the ER (pH 7.0;  $E_{\text{solution}} = -0.18$  V), 1/3 of PDI active sites contain a reactive thiolate.<sup>16,24</sup> Moreover, the high (less negative) reduction potential of PDI renders the protein as a weak disulfide-reducing agent, ensuring that ample time is available for the catalyst to rearrange all of the disulfide bonds before reducing its protein substrate to “escape” (Fig. 1). If necessary, however, the second active-site cysteine residue can engage to rescue the enzyme from non-productive mixed-disulfide intermediates.<sup>7,25,26</sup>

<sup>a</sup>Department of Chemistry, University of Wisconsin–Madison, 1101 University Avenue, Madison, WI 53706, USA

<sup>b</sup>Molecular & Cellular Pharmacology Graduate Training Program, University of Wisconsin–Madison, 1300 University Avenue, Madison, WI 53706, USA

<sup>c</sup>Department of Biochemistry, University of Wisconsin–Madison, 433 Babcock Drive, Madison, WI 53706, USA

†Electronic supplementary information (ESI) available: Synthetic and analytical procedures. See DOI: 10.1039/c4ob01738b

‡These authors contributed equally to this work.

Efficient oxidative protein folding requires a redox environment that supports both thiol oxidation and disulfide-bond isomerization. *In vitro* and *in cellulo*, this environment can be provided by a redox buffer consisting of reduced and oxidized glutathione. For example, the oxidative folding of a favorite model protein, bovine pancreatic ribonuclease (RNase A; EC 3.1.27.5), occurs readily in the presence of 1 mM glutathione (GSH) and 0.2 mM oxidized glutathione (GSSG).<sup>27</sup> Adding PDI accelerates the process, but the large-scale use of PDI as a catalyst for folding proteins *in vitro* is impractical due to its high cost and conformational instability, and the complexity imposed by its separation from a substrate protein. Accordingly, the development of small-molecule PDI mimics has become a high priority.

To date, most PDI mimics have been designed to replicate the physicochemical properties of the CGHC active site—low thiol  $pK_a$  and high disulfide  $E^\circ$ .<sup>28</sup> Previously, we reported on ( $\pm$ )-*trans*-1,2-bis(mercaptoacetamido)cyclohexane (**1**; BMC) (Fig. 2), a small molecule that catalyzes the formation of native disulfide bonds in proteins, both *in vitro* and *in cellulo*.<sup>29</sup> In 2005, other workers screened 14 reagents for their ability to fold a variety of proteins, and concluded that BMC was the best of known small-molecule catalysts.<sup>30</sup> Though effective, BMC has shortcomings. For example, its low disulfide  $E^\circ$  renders the compound too reducing for optimal catalysis of disulfide-bond isomerization. Subsequently, various CXXC and CXC peptides, aromatic thiols, and selenium-based catalysts were developed and employed with some success.<sup>31–42</sup> Nevertheless, these organocatalysts had non-optimal thiol  $pK_a$  and

disulfide  $E^\circ$  values. Moreover, they did not mimic a hallmark of enzymic catalysts—binding to the substrate.<sup>43</sup>

The b and b' domains of PDI have an exposed hydrophobic patch. The two patches unite to form a continuous hydrophobic surface between the two active sites.<sup>10,12,13,44,45</sup> This hydrophobic surface could entice PDI to bind to unfolded or misfolded proteins, which tend to expose more hydrophobic residues than do proteins in their native state.<sup>46</sup> Accordingly, we set out to design organocatalysts that not only have low thiol  $pK_a$  and high disulfide  $E^\circ$  values but also emulate substrate binding by PDI. We were inspired by the demonstrated ability of the hydrophobic effect to induce proximity in aqueous solution and thereby accelerate a variety of chemical reactions, such as O→N acyl transfer,<sup>47,48</sup> ester hydrolysis,<sup>49,50</sup> and dithiol oxidation.<sup>51,52</sup> We reasoned that analogous induced proximity could enhance disulfide-bond isomerization in a misfolded protein, which is the key step in oxidative protein folding.<sup>7,16</sup>

We reasoned that dithiol **2** (Fig. 2) would provide an appropriate scaffold for the development of useful catalysts. We were drawn to dithiol **2** for three reasons. First, its mercaptoacetamido groups are known to have low thiol  $pK_a$  values.<sup>29,53</sup> Secondly, the disulfide bond of its oxidized form resides in a large, 13-membered ring containing two secondary amides, which should lead to a high reduction potential. Finally, dithiol **2** has an amino group that can be condensed with hydrophobic carboxylic acids to mimic the b and b' domains of PDI.

Our experimental work commenced with the synthesis of dithiol **2** from diethylenetriamine in a few high-yielding steps (see: ESI†). To determine its thiol  $pK_a$  values, we monitored its  $A_{238\text{ nm}}$  as a function of pH.<sup>29,54</sup> We found  $pK_a$  values of  $8.0 \pm 0.2$  and  $9.2 \pm 0.1$  (Table 1). These values are slightly less than those of BMC, presumably due to the additional electronegative nitrogen atom. To determine the reduction potential of its




Fig. 2 Small-molecule PDI mimics synthesized and assessed in this study.

Table 1 Properties of PDI and mimics 1–8

Catalyst	$pK_a$	Disulfide $E^\circ$	$\log P^a$	Folding yield <sup>b</sup> (%)
(None)	—	—	—	$45 \pm 2$
PDI	6.7 <sup>c</sup>	−0.180 V	—	$87 \pm 2$
<b>1</b> (BMC)	8.3; 9.9 <sup>d</sup>	−0.232 V	—	$42 \pm 2$
<b>2</b>	8.0; 9.2	−0.192 V	0.10	$50 \pm 2$
<b>3</b>	ND	ND	−0.74	$45 \pm 2$
<b>4</b>	ND	ND	0.66	$54 \pm 4$
<b>5</b>	8.1; 9.3	−0.203 V	1.67	$57 \pm 1$
<b>6</b>	ND	ND	0.90	$60 \pm 2$
<b>7</b>	8.1; 9.4	−0.206 V	1.82	$66 \pm 2$
<b>8</b>	ND	ND	2.06	ND

<sup>a</sup> Values were calculated for dimethylamine in dithiol **2** and the tertiary amide moiety in dithiols **3–8** (e.g., *N,N*-dimethylacetamide for dithiol **3**) with software from Molinspiration (Slovenský Grob, Slovak Republic), and are similar to known experimental values.<sup>63</sup> <sup>b</sup> Values are for the unscrambling of sRNase A to give native RNase A by 1 mM catalyst in 5 h, as in Fig. 4. <sup>c</sup> Value for the N-terminal cysteine residue in the active site of PDI.<sup>24</sup> <sup>d</sup> Values are from ref. 29. ND, not determined.




Fig. 3 Scheme showing the connectivity of the four disulfide bonds in native RNase A. There are 104 other fully oxidized forms.

oxidized form, we equilibrated equimolar amounts of dithiol 2 and oxidized  $\beta$ -mercaptoethanol, and quantified the amount of each reduced and oxidized species with analytical HPLC.<sup>29,55</sup> We found a disulfide  $E^\circ$  value of  $(-0.192 \pm 0.003)$  V. This value indicates that dithiol 2 is a weaker reducing agent than is BMC, which is consistent with BMC being more preorganized for disulfide-bond formation. Finally, to probe the effect of increasing hydrophobicity on catalyzing the formation of native disulfide bonds in proteins, we synthesized dithiols 3–8. We isolated dithiols 3–6 as colorless oils, and dithiols 7 and 8 as white solids. None had a strong odor.

Enzymatic catalysis provides an extremely sensitive measure of native protein structure.<sup>56</sup> RNase A contains eight cysteine residues, which could form 105 ( $= 7 \times 5 \times 3 \times 1$ ) distinct fully oxidized species, only one of which gives rise to enzymatic activity (Fig. 3).<sup>57,58</sup> Accordingly, we tested the ability of this panel of compounds to catalyze the isomerization of “scrambled” RNase A (sRNase A), which is a random mixture of oxidized species, to its native state. The isomerization reaction was monitored by measuring the gain of catalytic activity.<sup>59</sup> Dithiol 8 was excluded from the analysis due to its low solubility in aqueous solution.

Some, but not all, of the PDI mimics led to a significant increase in the yield of oxidative protein folding (Fig. 4A). Most notably, the data with dithiols 2–7 revealed an overall trend toward higher yield with increasing hydrophobicity of the pendant carboxamide (Fig. 4B). This trend culminated with dithiol 7, which increased the yield of folded RNase A by 47% compared to that in the absence of a catalyst. These data contrast markedly with those using monothiols (e.g., glutathione), which reduce the yield of properly folded protein by favoring the accumulation of mixed-disulfide species.<sup>27</sup>

The apparent correlation of catalytic efficacy with hydrophobicity could be due to a physicochemical property other than hydrophobicity. Accordingly, we determined the thiol  $pK_a$  and disulfide  $E^\circ$  values of the most efficacious dithiols containing an alkyl (5) and aryl (7) carboxamide. We found dithiol 5 to have thiol  $pK_a$  values of 8.1 and 9.3 and a disulfide  $E^\circ$  value of  $-0.203$  V (Table 1). We found dithiol 7 to have similar physicochemical properties, with thiol  $pK_a$  values of 8.1 and 9.4 and a disulfide  $E^\circ$  value of  $-0.206$  V. Both of these compounds possess thiol acidity and disulfide stability similar to those of parent dithiol 2, affirming that hydrophobicity is indeed correlative with catalytic efficacy.

Our data are the first to indicate that adding a hydrophobic moiety to a small-molecule PDI mimic can have a profound effect on its ability to catalyze disulfide-bond isomerization. Still, none of the organocatalysts were as efficacious as PDI




Fig. 4 Catalysis of disulfide-bond isomerization by PDI and PDI mimics 1–7. (A) Graph of the time-course for the isomerization of sRNase A to give native RNase A. All assays were performed in triplicate at 30 °C in 50 mM Tris-HCl buffer, pH 7.6, containing GSH (1.0 mM), GSSG (0.2 mM), and PDI or dithiol 1–7 (1.0 mM). (B) Graph of the yield of native RNase A achieved by PDI mimics 2–7 after 5 h as a function of the  $\log P$  value of its side chain (Table 1).

itself. We note, however, that the molecular mass of PDI (57 kDa) is  $>10^2$ -fold greater than any of its mimics, enabling optimization of substrate binding and turnover beyond that attainable with small-molecule catalysts. Also, each molecule of PDI has two active sites, and thus provides a higher concentration of dithiol than do the organocatalysts.

Like the substrate-binding domains of PDI, the hydrophobicity of dithiols 4–7 likely encourages their interaction with unfolded or misfolded proteins.<sup>10,12,13,44,45,60,61</sup> Dithiols having moieties with higher  $\log P$  values perform better, and aromatic moieties seem to be especially efficacious (Fig. 4B). We note that a more hydrophobic catalyst could also increase the rate of the underlying thiol–disulfide interchange chemistry, as nonpolar environments are known to lower the free energy of activation for this reaction.<sup>62</sup>

## Conclusions

We have designed, synthesized, and characterized novel organocatalysts that enhance the efficiency of oxidative protein folding. Moreover, we have demonstrated that increasing the hydrophobicity of the catalysts has a marked effect on their catalytic efficacy. The production of proteins that contain disulfide bonds by recombinant DNA technology often leads to the aggregation of misfolded proteins.<sup>64,65</sup> These aggregates must be reduced, denatured, and solubilized to enable proper folding. Approximately 20% of all human proteins<sup>66</sup> and many proteins of high pharmaceutical relevance<sup>67,68</sup> contain at least one disulfide bond between cysteine residues. For example, antibodies contain at least 12 intrachain and 4 interchain disulfide bonds,<sup>69</sup> and there are >300 distinct antibodies in clinical development,<sup>70</sup> including ~30 antibody–drug conjugates.<sup>71</sup> The ability to mimic the essential function of PDI<sup>7,16</sup> in a small molecule could have a favorable impact on the production of antibodies and other biologics, and usher in a new genre of organocatalysts for oxidative protein folding.

## Acknowledgements

K.A.A. was supported by a predoctoral fellowship from the PhRMA Foundation and by Molecular and Cellular Pharmacology Training Grant T32 GM008688 (NIH). This work was supported by grant R01 GM044783 (NIH). NMR spectra were obtained at NMRFAM, which is supported by grant P41 GM103399 (NIH).

## Notes and references

- Biochemistry of the SH Group: The Occurrence, Chemical Properties, Metabolism and Biological Function of Thiols and Disulfides*, ed. P. C. Jocelyn, London, U.K., 1972.
- Oxidative Folding of Peptides and Proteins*, ed. J. Buchner and L. Moroder, The Royal Society of Chemistry, Cambridge, UK, 2009.
- M. Lindahl, A. Mata-Cabana and T. Kieselbach, *Antioxid. Redox Signaling*, 2011, **14**, 2581–2642.
- O. B. Oka and N. J. Bulleid, *Biochim. Biophys. Acta*, 2013, **1833**, 2425–2429.
- C. B. Anfinsen, *Science*, 1973, **181**, 223–230.
- A. S. Robinson, V. Hines and K. D. Wittrup, *Biotechnology*, 1994, **12**, 381–384.
- M. C. A. Laboissière, S. L. Sturley and R. T. Raines, *J. Biol. Chem.*, 1995, **270**, 28006–28009.
- Prolyl Hydroxylase, Protein Disulfide Isomerase, and Other Structurally Related Proteins*, ed. N. A. Guzman, Marcel Dekker, New York, NY, 1998.
- K. J. Woycechowsky and R. T. Raines, *Curr. Opin. Chem. Biol.*, 2000, **4**, 533–539.
- R. B. Freedman, P. Klappa and L. W. Ruddock, *EMBO Rep.*, 2002, **3**, 136–140.
- E. A. Kersteen and R. T. Raines, *Antioxid. Redox Signaling*, 2003, **5**, 413–424.
- G. Tian, S. Xiang, R. Noiva, W. J. Lennarz and H. Schindelin, *Cell*, 2006, **124**, 61–73.
- C. W. Gruber, M. Cemazar, B. Heras, J. L. Martin and D. J. Craik, *Trends Biochem. Sci.*, 2006, **31**, 455–464.
- A. Y. Denisov, P. Maattanen, C. Dabrowski, G. Kozlov, D. Y. Thomas and K. Gehring, *FEBS J.*, 2009, **276**, 1440–1449.
- E. A. Kersteen, S. R. Barrows and R. T. Raines, *Biochemistry*, 2005, **44**, 12168–12178.
- P. T. Chivers, M. C. A. Laboissière and R. T. Raines, *EMBO J.*, 1996, **15**, 2659–2667.
- A. Holmgren, *J. Biol. Chem.*, 1979, **254**, 9627–9632.
- J. C. Edman, L. Ellis, R. W. Blacher, R. A. Roth and W. J. Rutter, *Nature*, 1985, **317**, 267–270.
- N. J. Darby and T. E. Creighton, *Biochemistry*, 1995, **34**, 3576–3587.
- H. F. Gilbert, *Adv. Enzymol.*, 1990, **63**, 69–172.
- P. T. Chivers, K. E. Prehoda and R. T. Raines, *Biochemistry*, 1997, **36**, 4061–4066.
- H. C. Hawkins and R. B. Freedman, *Biochem. J.*, 1991, **275**, 335–339.
- J. Lundstrom and A. Holmgren, *Biochemistry*, 1993, **32**, 6649–6655.
- C. Hwang, A. J. Sinskey and H. F. Lodish, *Science*, 1992, **257**, 1496–1502.
- K. W. Walker, M. M. Lyles and H. F. Gilbert, *Biochemistry*, 1996, **35**, 1972–1980.
- K. W. Walker and H. F. Gilbert, *J. Biol. Chem.*, 1997, **272**, 8845–8848.
- M. M. Lyles and H. F. Gilbert, *Biochemistry*, 1991, **30**, 619–625.
- W. J. Lees, *Curr. Opin. Chem. Biol.*, 2008, **12**, 740–745.
- K. J. Woycechowsky, K. D. Wittrup and R. T. Raines, *Chem. Biol.*, 1999, **6**, 871–879.
- M. S. Willis, J. K. Hogan, P. Prabhakar, X. Liu, K. Tsai, Y. Wei and T. Fox, *Protein Sci.*, 2005, **14**, 1818–1826.
- K. J. Woycechowsky, B. A. Hook and R. T. Raines, *Biotechnol. Prog.*, 2003, **19**, 1307–1314.
- K. J. Woycechowsky and R. T. Raines, *Biochemistry*, 2003, **42**, 5387–5394.
- J. D. Gough, J. M. Gargano, A. E. Donofrio and W. J. Lees, *Biochemistry*, 2003, **42**, 11787–11797.
- J. D. Gough and W. J. Lees, *J. Biotechnol.*, 2005, **115**, 279–290.
- J. D. Gough and W. J. Lees, *Bioorg. Med. Chem.*, 2005, **15**, 777–781.
- J. D. Gough, E. J. Barrett, Y. Silva and W. J. Lees, *J. Biotechnol.*, 2006, **125**, 39–47.
- J. Beld, K. J. Woycechowsky and D. Hilvert, *Biochemistry*, 2008, **47**, 6985–6987.
- J. Beld, K. J. Woycechowsky and D. Hilvert, *Biochemistry*, 2009, **48**, 4662–4662.

- 39 J. Beld, K. J. Woycechowsky and D. Hilvert, *J. Biotechnol.*, 2010, **150**, 481–489.
- 40 G. Z. Wang, X. Y. Dong and Y. Sun, *Biochem. Eng. J.*, 2011, **55**, 169–175.
- 41 A. S. Patel and W. J. Lees, *Bioorg. Med. Chem.*, 2012, **20**, 1020–1028.
- 42 W. J. Lees, *ChemBioChem*, 2012, **13**, 1725–1727.
- 43 W. R. Jencks, *Catalysis in Chemistry and Enzymology*, McGraw–Hill, New York, NY, 1969.
- 44 S. R. Shouldice, B. Heras, P. M. Walden, M. Totsika, M. A. Schembri and J. L. Martin, *Antioxid. Redox Signaling*, 2011, **14**, 1729–1760.
- 45 F. X. Kober, W. Koelmel, J. Kuper, J. Drechsler, C. Mais, H. M. Hermanns and H. Schindelin, *J. Biol. Chem.*, 2013, **288**, 2029–2039.
- 46 L. Lins and R. Brasseur, *FASEB J.*, 1995, **9**, 535–540.
- 47 J. R. Knowles and C. A. Parsons, *Chem. Commun.*, 1967, 755–757.
- 48 C. A. Blyth and J. R. Knowles, *J. Am. Chem. Soc.*, 1971, **93**, 3017–3021.
- 49 J. R. Knowles and C. A. Parsons, *Nature*, 1969, **221**, 5553–5554.
- 50 C. A. Blyth and J. R. Knowles, *J. Am. Chem. Soc.*, 1971, **93**, 3021–3027.
- 51 G. Z. Wang, X. Y. Dong and Y. Sun, *Biotechnol. Prog.*, 2011, **27**, 377–385.
- 52 H. Liu, X. Y. Dong and Y. Sun, *Biochem. Eng. J.*, 2013, **79**, 29–32.
- 53 W. J. Lees, R. Singh and G. M. Whitesides, *J. Org. Chem.*, 1991, **56**, 7328–7331.
- 54 J. C. Lukesh, M. J. Palte and R. T. Raines, *J. Am. Chem. Soc.*, 2012, **134**, 4057–4059.
- 55 G. V. Lamoureux and G. M. Whitesides, *J. Org. Chem.*, 1993, **58**, 633–641.
- 56 J. R. Knowles, *Science*, 1987, **236**, 1252–1258.
- 57 R. T. Raines, *Chem. Rev.*, 1998, **98**, 1045–1066.
- 58 T. A. Klink, K. J. Woycechowsky, K. M. Taylor and R. T. Raines, *Eur. J. Biochem.*, 2000, **267**, 566–572.
- 59 B. R. Kelemen, T. A. Klink, M. A. Behlke, S. R. Eubanks, P. A. Leland and R. T. Raines, *Nucleic Acids Res.*, 1999, **27**, 3696–3701.
- 60 L. W. Guddat, J. C. Bardwell, T. Zander and J. L. Martin, *Protein Sci.*, 1997, **6**, 1148–1156.
- 61 H. F. Gilbert, *J. Biol. Chem.*, 1997, **272**, 29399–29402.
- 62 P. A. Fernandes and M. J. Ramos, *Chem. – Eur. J.*, 2004, **10**, 257–266.
- 63 J. Sangster, *J. Phys. Chem. Ref. Data*, 1989, **18**, 1111–1227.
- 64 F. A. O. Marston, *Biochem. J.*, 1986, **240**, 1–12.
- 65 E. De Bernardez Clark, *Curr. Opin. Biotechnol.*, 1998, **9**, 157–163.
- 66 P. L. Martelli, P. Fariselli and R. Casadio, *Proteomics*, 2004, **4**, 1665–1671.
- 67 R. C. Fahey, J. S. Hunt and G. C. Windham, *J. Mol. Evol.*, 1977, **10**, 155–160.
- 68 J. M. Thornton, *J. Mol. Biol.*, 1981, **151**, 261–287.
- 69 H. Liu and K. May, *mAbs*, 2012, **4**, 17–23.
- 70 Pharmaceutical Research and Manufacturers of America report “Medicines in Development—Biologics, 2013 Report”.
- 71 A. Mullard, *Nat. Rev. Drug Discov.*, 2013, **12**, 329–332.